Research
Sermorelin research: what the GH/IGF-1 evidence actually shows
The mechanism, the human trials, and the interpretation — paced and cited.
Before the details
Here is the sermorelin research in a few plain lines. Sermorelin tells the pituitary to release the body's own growth hormone, which in turn raises IGF-1 (a hormone made by the liver that does much of growth hormone's work). In children who lacked enough growth hormone, it sped up growth. In older men, two weeks of dosing pushed their growth-hormone and IGF-1 numbers back toward youthful levels. A related, longer-acting cousin improved thinking scores and lowered body fat in older adults. The catch: most of these studies are short, and experts say the anti-aging case is not yet proven. This page lays out each finding and cites it.
Mechanism: the GHRH-receptor to GH to IGF-1 cascade
Sermorelin is the 1-29 fragment of GHRH and the shortest piece retaining full GHRH activity [1]. It engages the GHRH receptor on anterior-pituitary somatotrophs and turns on adenylate cyclase / cAMP / protein kinase A signaling, raising GH gene transcription and triggering pulsatile GH release [1]. GH then drives hepatic IGF-1, which mediates GH's downstream effects and feeds back to restrain secretion [1].
The defining feature is that the loop stays closed. Somatostatin (the off-switch) and IGF-1 negative feedback remain operative, so the natural pulsatile pattern is preserved rather than overridden [4]. That is the mechanistic basis for the editorial argument that a physiologic secretagogue may be a more physiologic route to adult-onset GH insufficiency than recombinant GH [7].
What the efficacy evidence shows
Does sermorelin work? In its formerly approved pediatric setting, once-daily subcutaneous GHRH(1-29) accelerated linear growth in GH-deficient children: first-year height velocity rose from about 4.1 cm/year to roughly 7-8 cm/year, without excessive IGF-1 generation [2]. In healthy older men (mean 68 years), 0.5 mg and 1 mg twice daily for 14 days produced dose-related increases in 24-hour GH and IGF-1; after the high dose, GH/IGF-1 parameters no longer differed from those of young men, with no effect on fasting glucose [3].
The efficacy picture is therefore real but bounded. The pediatric and short-term adult endocrine effects are well documented; a durable adult anti-aging benefit is not. An Annals of Internal Medicine editorial judged secretagogue use to prevent or treat the effects of aging not yet justified by the evidence [6].
Research-studied effects of GHRH(1-29)
Sermorelin benefits, as documented in the research literature, center on the GH/IGF-1 axis. Fourteen days of GHRH(1-29) dosing in older men reversed age-related declines in GH and IGF-1, returning those measures to a young-adult range at the high dose [3]. In a randomized, double-blind, placebo-controlled trial of 152 older adults, 20 weeks of a stabilized GHRH analogue (tesamorelin) had a favorable effect on cognition (P=0.03), raised IGF-1 by 117% within the physiologic range, and reduced percent body fat by 7.4% [8].
Those are the documented, study-attributed effects — and the boundary matters. The body-composition and cognition figures above come from a GHRH-analogue (tesamorelin) trial, presented as drug-class GHRH-analogue findings, not as proven sermorelin outcomes [8]. The corpus flags that anti-aging and body-composition marketing outpaces the rigorous long-term evidence [6].
Recent reviews and the 2025 synthesis
A 2025 Nature Reviews Endocrinology review synthesizes the biology of growth-hormone-releasing hormone and its analogues across health and disease — GHRH-receptor signaling, the GH/IGF-1 axis, and therapeutic applications of GHRH agonists and antagonists — situating sermorelin within an active research program [9].
Sports-medicine reviews from 2026 are more cautionary. One critical review classifies sermorelin among GHRH-analogue peptides marketed for performance enhancement and reports a largely unregulated supply chain yielding frequently mislabeled or contaminated products [11]. A narrative review explicitly including sermorelin describes a parallel gray market of unapproved compounds where rigorous human safety data are scarce [12], and a structured review concludes GH-axis secretagogues remain investigational with uncertain safety profiles [13]. These are summarized in sermorelin side effects in the literature.
Does sermorelin work? Comparisons and open questions
Does sermorelin work?
In its formerly approved pediatric setting, once-daily subcutaneous GHRH(1-29) accelerated linear growth in GH-deficient children [2]; in older men, 14 days of dosing reversed age-related declines in GH and IGF-1 [3]. Authorities caution that secretagogue use for aging is not yet established [6].
How long does it take for sermorelin to work?
Pharmacology shows GH rises within hours of a dose and stays elevated about 3 hours despite rapid clearance [5]; measurable IGF-1 and body-composition changes in trials were reported over weeks — 14 days in older men [3], 20 weeks in the cognition trial [8].
How does sermorelin compare to CJC-1295?
Both engage the GHRH receptor, but native sermorelin (GHRH(1-29)) is rapidly cleared — a half-life on the order of 10-12 minutes IV — which is exactly why longer-acting analogues were developed; modifying GHRH(1-29)NH2 increased half-life and decreased metabolic clearance, and DAC technology underlies CJC-1295 [5].
Sermorelin vs ipamorelin: what is the difference?
Sermorelin is a GHRH analogue acting on the pituitary GHRH receptor; ipamorelin is a growth-hormone-releasing peptide (GHRP) acting on the ghrelin/GHS receptor — a different mechanism within the same secretagogue family [1].
How does sermorelin differ from direct HGH injections?
Sermorelin acts upstream on the pituitary to stimulate the body's own pulsatile GH release with somatostatin and IGF-1 feedback intact, rather than supplying exogenous GH; an editorial argued this physiologic secretagogue approach may be more physiologic than recombinant GH for adult-onset GH insufficiency [7].
Does sermorelin affect the brain?
In a randomized trial, a GHRH analogue had a favorable effect on cognition in older adults, with and without mild cognitive impairment, over 20 weeks of dosing [8].
Why is it recommended to inject sermorelin at night?
Slow-wave sleep coincides with the body's largest nocturnal GH pulse, so research protocols commonly used bedtime dosing to align GHRH stimulation with that natural nighttime release — a description of study design [8], not a dosing recommendation.
Does sermorelin actually help with sleep, or is it waking me up instead?
The corpus links GHRH to slow-wave sleep and the largest nocturnal GH pulse, and notes the sleep-endocrine effect is time-of-administration dependent; the dealt evidence describes a circadian-dependent effect rather than a uniform one and offers no individual experience guidance [8].
Will sermorelin raise my IGF-1 levels?
Raising IGF-1 is a central, well-documented effect: 14 days of GHRH(1-29) increased 24-hour GH and IGF-1 dose-dependently in older men [3], and a GHRH analogue raised IGF-1 by 117% within the physiologic range in a 20-week trial [8].
Does sermorelin affect testosterone?
Sermorelin acts on the GH/IGF-1 axis, not the gonadal axis. The dealt evidence describes GH and IGF-1 effects [3] rather than a direct testosterone effect, so the corpus does not support a testosterone claim.
Does sermorelin burn fat? Is it effective for weight loss?
GHRH-axis stimulation can change body composition: in the cognition trial a GHRH analogue reduced percent body fat by 7.4% [8]. That is a drug-class GHRH-analogue finding, presented factually rather than as a proven sermorelin fat-loss or weight-loss claim; the corpus flags that body-composition marketing outpaces the rigorous evidence [6].
Does sermorelin build muscle?
The dealt evidence does not contain a sermorelin muscle-hypertrophy trial; it links GHRH-axis stimulation to IGF-1 elevation and body-composition change [8]. Any muscle framing is candidate rationale via the GH/IGF-1 axis, not proven muscle-building.
Can sermorelin or GHRH improve cognition in older adults?
In a randomized, double-blind, placebo-controlled trial of 152 older adults (66 with mild cognitive impairment), 20 weeks of a GHRH analogue had a favorable effect on cognition (P=0.03) while raising IGF-1 by 117% and reducing percent body fat by 7.4% [8].